Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences
ALACHUA, Fla. and TAMPA, Fla., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that management is scheduled to participate in three upcoming investor conferences:
Raymond James 47th Annual Institutional Investors Conference
Participation: Presentation and 1x1 investor meetings
Date/Time: Presentation Tuesday, March 3, 2026, 3:25 PM ET
Webcast Link: Raymond James/Axogen Presentation
Leerink Global Healthcare Conference
Participation: Fireside Chat and 1x1 investor meetings
Date/Time: Fireside Chat Monday, March 9, 2026, 1:00 PM ET
Webcast Link: Leerink/Axogen Fireside Chat
The Citizens Life Sciences Conference
Participation: Fireside Chat and 1x1 investor meetings
Date/Time: Fireside Chat Tuesday, March 10, 2026, 12:30 PM ET
Webcast Link: Citizens/Axogen Fireside Chat
Webcast events can be accessed live through the Investors page at www.axogeninc.com. For those unable to listen to the live broadcast, the replay will be archived for 90 days and available on the Investors page at www.axogeninc.com.
About Axogen
Axogen (Nasdaq: AXGN) is focused on the science, development and commercialization of technologies for peripheral nerve repair. With a mission to make nerve repair the expected standard of care, Axogen advances the field through research, education, and collaboration with surgeons and healthcare providers across a global network.
Axogen’s product portfolio includes Avance® (acellular nerve allograft-arwx), Avance® Nerve Graft, Axoguard Nerve Connector®, Axoguard Nerve Protector®, Axoguard HA+ Nerve Protector™, Axoguard Nerve Cap®, and Avive+ Soft Tissue Matrix™.
Contact:
Axogen, Inc.
InvestorRelations@axogeninc.com
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
